Filing Flows › Companies › Globus Medical › Timeline
Globus Medical stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+15.2% to $71.05
Globus Medical (GMED) stock rose 15% over the last 252 sessions, to $71.05. On the way it reported 5 quarters, its insiders filed 3 open-market trades and 3 Form 144 notices of planned sales, and the company filed 2 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 2.8% | −6.7% (−2.2% vs SPY) | — | — |
| Nov 4, 2026 | Form 144 | Form 144: Ann D Rhoads plans to sell $425K | +9.0% (+7.4% vs SPY) | — | — |
| Sep 15, 2026 | Form 144 | Form 144: James R Tobin plans to sell $2.2M | −1.4% (−1.0% vs SPY) | −2.0% (−3.9% vs SPY) | +0.7% (−1.8% vs SPY) |
| Sep 15, 2026 | Insider sale | Tobin James R sold $2.2M | −1.4% (−1.0% vs SPY) | −2.0% (−3.9% vs SPY) | +0.7% (−1.8% vs SPY) |
| Aug 18, 2026 | Form 144 | Form 144: Stephen T Zarrilli plans to sell $2.2M | +1.5% (+2.2% vs SPY) | −1.2% (0.0% vs SPY) | −12.3% (−9.9% vs SPY) |
| Aug 18, 2026 | Insider sale | Zarrilli Stephen T sold $2.2M | +1.5% (+2.2% vs SPY) | −1.2% (0.0% vs SPY) | −12.3% (−9.9% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 21.9% | +0.7% (+0.8% vs SPY) | +6.2% (+5.8% vs SPY) | −3.1% (−3.5% vs SPY) |
| Jun 5, 2026 | Insider sale | Davidar David D sold $2.0M | 0.0% (+2.6% vs SPY) | +0.6% (+3.2% vs SPY) | −1.5% (−0.5% vs SPY) |
| Jun 4, 2026 | 8-K | Directors and officers: departures, appointments, pay | 0.0% (+2.6% vs SPY) | +0.6% (+3.2% vs SPY) | −1.5% (−0.5% vs SPY) |
| May 7, 2026 | Earnings | Earnings: beat the EPS estimate by 21.7% | −4.8% (−4.5% vs SPY) | −16.6% (−17.8% vs SPY) | −10.9% (−11.4% vs SPY) |
| Mar 23, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.1% (−0.8% vs SPY) | −4.3% (−0.7% vs SPY) | +8.5% (+0.3% vs SPY) |
| Feb 24, 2026 | Earnings | Earnings: beat the EPS estimate by 11.0% | −1.6% (−2.4% vs SPY) | +0.4% (−0.1% vs SPY) | −7.9% (−3.8% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: beat the EPS estimate by 51.1% | +0.3% (+1.4% vs SPY) | +32.0% (+31.1% vs SPY) | +39.3% (+38.1% vs SPY) |
Insiders’ record here
In the year on the chart, Globus Medical's insiders reported 0 open-market buys ($0) and 3 sales ($6.4M). Of the 1 old enough to score, 1 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −6.6%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Globus Medical: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.